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Introducing Alzheimer’s & Dementia: Translational Research & Clinical
Interventions, an open access journal of the Alzheimer’s AssociationAlzheimer’s &Dementia: Translational Research&Clin-
ical Interventions is an open access journal of the Alz-
heimer’s Association. The journal’s mission is to advance
and expedite clinical translational research in Alzheimer dis-
ease and age-related cognitive impairment into improved
care and therapies, while promoting high-visibility, open ac-
cess communication across preclinical, clinical, and effec-
tiveness research areas.
The journal will promote the dissemination of knowledge
and research outcomes that inform translational research,
early and late-stage clinical trials and development, clinical
research bioinformatics, and clinical practice by providing
an open access vehicle for communication among preclini-
cal, translational, and clinical trials researchers.
By translational research we mean research that plans to
involve or includes humans and therapeutic interventions
that range from preclinical to late stage trials and health tech-
nology assessment. The interventions may include drugs, bi-
ologicals, devices, and the full range of psychotherapeutic,
psychosocial, and other non-pharmacological approaches,
as well as technology assessment and effectiveness, services
research, and clinical application. Thus, Alzheimer’s & De-
mentia: Translational Research & Clinical Interventions
covers therapeutics, clinical development, methods, clinical
research informatics, and trials for Alzheimer disease, age-
related cognitive impairment, and other conditions associ-
ated with cognitive impairment in late-life.1. Publishing in open access journals
There are several advantages of an online, open access
journal when compared with subscription-based, print
journals. These include rapid review, publication within
a few weeks of final acceptance, and the ability to post
full-color, high-resolution graphics, video clips, and sub-
stantial supplemental material, such as protocols, methods,
data forms, and programing code. Open access authors
hold the copyright to their article, and publication of their
articles meet the National Institutes of Health’s and other
funders’ requirements for rapid dissemination of research
outcomes.http://dx.doi.org/10.1016/j.trci.2015.06.002
2352-8737/  2015 The Author. Published by Elsevier Inc. on behalf of the Alzhe
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Open access journals hosted by major publishers charge
publishing fees in lieu of charging for subscriptions. Invited
commentaries, perspectives, reviews, correspondences,
communications, and images are not charged. Fees are sub-
stantially reduced for members of the Alzheimer Associa-
tion’s International Society to Advance Alzheimer’s
Research and Treatment (ISTAART). Many organizations
and funding agencies will pay the fee for authors [1,2].
Details about open access publishing for Alzheimer-
related research were discussed in our sister journal, Alz-
heimer’s & Dementia: Diagnosis, Assessment, & Disease
Monitoring and elsewhere [3,4].2. The Journal’s title and content
The content for Alzheimer’s & Dementia: Translational
Research & Clinical Interventions is guided and informed
by the Common Alzheimer’s Disease Research Ontology
[5], Categories C and E, in particular; and the International
Alzheimer’s Disease Research Portfolio that aims to capture
global Alzheimer research funding as well [6]. These cate-
gories include topics focused on the identification and devel-
opment of therapies for Alzheimer’s disease from early
discovery through late stage preclinical development, all
stages of clinical testing, interventions, and trials, as well
as non-pharmacological primary, secondary, and tertiary in-
terventions, including cognitive training, behavioral, neuro-
psychological interventions, outcomes, and treatment
development (Box 1).3. Publishing in Alzheimer’s & Dementia: Translational
Research & Clinical Interventions
Alzheimer’s &Dementia: Translational Research&Clin-
ical Interventions encourages the submission of studies
describing preclinical, translational research with potential
for clinical application, research from early human experi-
mentation (experimental medicine), clinical trials, preven-
tion studies, clinical research bioinformatics, systematic
reviews, metaanalyses, commentary, and perspectives that
have the potential to advance treatment of Alzheimer’simer’s Association. This is an open access article under the CC BY-NC-ND
Box 1
Common Alzheimer’s Disease Research Ontology
Category C. Translational research and clinical
interventions
1. Drug discovery
2. Preclinical therapy development
Pharmacological and non-pharmacological
interventions
3. Clinical trial design and methods
4. Proof of concept and feasibility trials
5. Prevention trials
6. Treatment trials – cognition
Various interventions
7. Treatment trials – neuropsychiatric, behav-
ioral and psychological comorbidity
Pharmacological and non-pharmacological
Category E. Care, support, and health economics
1. Care interventions and quality of life
2. Technology assisted care
3. Caregiver support
4. Cultural values and beliefs
5. Economic burden
(From: Refolo LM, et al. Alzheimer’s & Dementia.
2012;8:372-5 [1])
L.S. Schneider / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 1 (2015) 91-9392disease pathology, neurodegeneration, and cognitive impair-
ment, and improve patients’ lives. This is research that
bridges the laboratory and clinical settings, including molec-
ular characterization, discovery, formulation, prevention,
detection, diagnosis and treatment, with the overall goal of
improving the clinical care.
The journal will publish laboratory studies of novel ther-
apeutic interventions and clinical trials which evaluate new
pharmacological, non-pharmacological, psychosocial, and
environmental treatment paradigms from prevention to dis-
ease management. Studies describing public health and
health economics research with potential application to the
clinic or disease prevention are also encouraged.
The areas of clinical research informatics, i.e. informatics
applied to clinical research contexts, that the journal pro-
motes include (1) efficient and effective data collection
and acquisition for clinical trials; (2) protocol designs based
on prior clinical trials data; (3) patient recruitment; and (4)
adverse events, monitoring, regulatory approaches,
including clinical research data storage, processing and anal-
ysis, tools and technologies that facilitate clinical research,
metrics, statistics, outcomes and trials management, and
the informing of clinical research through analysis of large
datasets.
Alzheimer’s &Dementia: Translational Research&Clin-
ical Interventions intends to provide a communication
vehicle for reports on the “nuts and bolts” of clinicalresearch: methods advancements, procedures, protocols,
protocols design, implementation, outcomes, metrics, regu-
latory science, statistical modelling, and clinical research
bioinformatics.
The editors and an international editorial board of
clinician-scientists, scientists, and others will hold Alz-
heimer’s & Dementia: Translational Research & Clinical
Interventions to the same standards of the parent journal,
Alzheimer’s & Dementia. This online journal serves as an
alternative to the parent journal in order to cover the transla-
tional research areas that the Alzheimer’s & Dementia
cannot accomplish because of its mission and limited space.
Editorial and peer review is as rigorous for Alzheimer’s &
Dementia: Translational Research & Clinical Interventions
as it is for its parent journal.3.1. Types of articles
The journal invites the submission of original articles and
commentaries. These include commentaries, perspectives,
personal views, position papers, correspondence, images,
graphs, videos, narrative, full-length, or mini-reviews, sys-
tematic reviews and metaanalyses, and full-length and brief
research articles.
Examples of research articles include, but are not limited
to, preclinical drug development, clinical trials reports,
phase 1 to 3 clinical trials, such as dose-finding, safety, proof
of concept, and efficacy trials, clinical experimental
methods, designs (including protocols), outcomes develop-
ment, statistical methods, pooled analyses, simulations,
and modeling.
Narrative reviews should have a clearly stated topic, may
be invited by the editors or submitted without invitation.
Invited reviews will be peer-reviewed and edited. Uninvited
reviews will be evaluated by the editors for peer-review. Sys-
tematic reviews and metaanalyses are considered as research
articles. They may be full-length or brief, mini-reviews. The
key points are that they are preplanned, protocol-driven, and
address a hypothesis or question.
Commentaries may comment on current articles, policy,
clinical research, funding, regulatory issues, and similar.
They are opportunities to present particular views on a trans-
lational research or clinical trials topic in order to promote
innovation.
Perspectives provide an opportunity to present partic-
ular views on a topic, and may address any issue within
the translational research scope of the journal. Impor-
tantly, a perspective article should discuss implications
and next steps specifically, and should not leave the
reader hanging. Correspondence is welcomed, and may
address earlier publications or general topics relevant to
the journal.
All original articles should have a structured abstract
and a “Research in Context” section. The latter is essentially
a post script paragraph of 100 to 150 words that contains
the essential point of the article and requires authors to be
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questions.4. The editorial team
The Editor-in-Chief of Alzheimer’s & Dementia: Trans-
lational Research & Clinical Interventions, is Dr. Lon S.
Schneider. The Senior Associate Editors are Drs. Steven T.
DeKosky, Hiroko Dodge, Miia Kivipelto, Simon Lovestone,
Rupert McShane, and Mary Sano. Each has made important
contributions to translational research, and will provide
breadth, depth, experience, and perspective on the journal’s
direction.
The participation of a broadly-skilled, large editorial
board representing academics, research, industry, and char-
ity is another extremely valuable contribution to the start
of this new venture (http://www.trci.alzdem.com/content/
edboard). Dr. Zaven S. Khachaturian, Editor-in-Chief of
Alzheimer’s & Dementia, has provided immeasurable and
wise guidance and support. Dr. Ara S. Khachaturian, Exec-
utive Editor forAlzheimer’s &Dementia, Dr. Peter J. Snyder,
Editor-in-Chief of Alzheimer’s & Dementia: Diagnosis,
Assessment, & Disease Monitoring, (http://www.dadm.
alzdem.com), and Dr. Kathleen M. Hayden, Senior Asso-
ciate Editor for Alzheimer’s & Dementia and Executive Ed-
itor of the two Alzheimer’s & Dementia open access journals
provide substantial support.
Mr. Terry Materese, Executive Publisher at Elsevier leads
the publishing effort; and the Alzheimer’s Association
liaises with the Alzheimer’s & Dementia executive editor
through Drs. Heather Snyder, and Dr. Maria Carrillo, Vice
President of Medical and Scientific Relations for the Alz-
heimer’s Association.The editors of Alzheimer’s & Dementia: Translational
Research & Clinical Interventions hope that the journal
will be widely visited, read, and valued by people interested
in late-life cognitive impairment and that the journal is seen
as an important resource for the field.Lon S. Schneider, MD
Keck School of Medicine of the University of Southern
California
Los Angeles, CA, USA
E-mail addresses: lschneid@usc.edu or http://twitter.com/
LonSchneiderMD or http://twitter.com/alzdemjournals
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